Feuerstein's Biotech-Stock Mailbag

I'm starting to get a lot of email about the big cancer confab in June, otherwise known as the American Society of Clinical Oncology, or ASCO, annual meeting. In particular, there is considerable reader interest in ImClone Systems (IMCL Quote) because of the highly anticipated presentation of data from the phase III Erbitux lung cancer study known as FLEX.

In order to get to most of your questions, I've taken a different tack with this week's Mailbag, assembling my own Q&A on ImClone below. It's like a conversation with myself, but it encompasses all the major questions posted to me recently by readers. If there's something I don't cover, please let me know.

What's so important about the FLEX study data? ...